Allergic asthma is a type of asthma that is triggered by exposure to allergens, such as dust mites, pollen, pet dander, and mold spores. When a person with allergic asthma is exposed to these allergens, their immune system overreacts and produces an inflammatory response in the airways, which causes them to become inflamed and narrow, leading to symptoms such as wheezing, coughing, shortness of breath, and chest tightness. Allergic asthma is one of the most common types of asthma, and it affects people of all ages. It can be diagnosed through a combination of medical history, physical exam, and breathing tests. Treatment for allergic asthma typically involves avoiding triggers as much as possible, using medications such as inhaled corticosteroids and bronchodilators to manage symptoms and in some cases, immunotherapy to desensitize the immune system to specific allergens. Yet, many experts feel that allergic asthma patients may be treated well with careful care if additional study is done to uncover therapeutic cure possibilities. In this respect, research is being conducted at some of the world’s most prestigious scientific institutes. Auburn University in the United States is one such institution where research was undertaken under the capable supervision of Dr. Amarjit Mishra.
Firstly, we should know that research is crucial in studying allergic asthma as it helps to deepen our understanding of the underlying mechanisms of the disease, identify new treatments, and develop strategies for preventing and managing asthma symptoms. Researchers can investigate which allergens are most commonly associated with allergic asthma in different populations and regions. This can help people with asthma to avoid triggers and take preventive measures. For instance, researchers such as Dr. Amarjit Mishra are exploring the biological processes that lead to the development of allergic asthma, including the role of inflammation, immune system responses, and genetics. This can help to develop new treatments and preventative strategies. Further, researchers can also test new medications and therapies for allergic asthma, including drugs that target specific inflammatory pathways or immune cells involved in the disease. They can also investigate the effectiveness of existing treatments in different patient populations. It has also been found that researchers can investigate new ways of diagnosing allergic asthma, including biomarkers in blood or other samples, imaging techniques, and other diagnostic tools which can help to improve the accuracy and speed of diagnosis, leading to more effective treatment.
Some of examples of recent research in allergic asthma include the research focused on identifying new biomarkers and developing targeted therapies to improve disease management. This has the potential to lead to personalized treatments and prevention strategies for individuals with allergic asthma. In such a scenario, a major contribution is made by Dr. Amarjit Mishra Ex-Assistant Professor at Auburn University, Alabama in the USA.
Who is Dr. Amarjit Mishra?
Dr. Amarjit Mishra was a well-known professor at Auburn University who, through his expertise and skills, has been actively pursuing research in the field of pulmonology, immunology, genetics, and cancer biology. Dr. Mishra received his doctorate from Oklahoma Center for Respiratory and Infectious Diseases, Department of Physiological Sciences, Oklahoma State University in the USA. He has been active in a variety of research initiatives. Most notably, he has been the principal investigator on many NIH-funded projects. In addition to his work on those projects, he has other publications published in prestigious journals. Ex-Assistant Professor Dr. Amarjit Mishra is a well-known member of the Auburn community and he has been conducting an extensive study in the field of pulmonology, particularly to better understand the mechanism of allergic asthma.
Dr. Amarjit Mishra’s Research on Allergic Asthma
Th2-high asthma (a condition linked with allergy-induced asthma), according to Dr. Amarjit Mishra, is shown in the clinic by raised levels of blood and sputum eosinophils, fractional exhaled nitric oxide, serum IgE, and type 2 cytokines IL4, IL5, and IL13. Natural killer cells and innate type 2 innate lymphoid cells regulate the innate Type 2 inflammatory response in the airways, whereas Th2 (T helper type 2) immune cells in the lungs create adaptive immunity. Nevertheless, the Th2-mediated lung adaptive immune response results in eosinophilic inflammation, which is accompanied by cytokine release of IL-5, IL-13, and IL-4. Moreover, allergen-induced Th2 inflammation is triggered by antigen-presenting dendritic cells, which in their juvenile condition rely on mitochondrial oxidative phosphorylation and is controlled by AMPK signaling. Some of Dr. Amarjit Mishra’s most significant research focused on the involvement of dendritic cells in the development of allergy-induced asthma. Dendritic cells are true antigen-presenting cells that play a critical role in the development of T cell-mediated adaptive immune responses to the inhaled aeroallergen HDM in allergic asthma. Dr. Mishra has also undertaken extensive in-vivo studies on ADAMTS7-deficient mice in order to determine the role of ADAMTS7 in house dust mites-induced airway inflammation. His research established for the first time that ADAMTS7 has a causative role in the development of Th2 immune responses to home dust mites in experimental allergen-induced asthma. His findings confirmed the involvement of the ADAMTS7 gene as a negative regulator of dendritic cell-mediated allergic airway inflammation in asthma. Dr. Amarjit Mishra also served as a member of a devoted team of researchers that discovered that the Irg1/itaconate metabolic pathway is a critical determinant of dendritic cell immune-priming activity and leads to persistent allergen-induced airway inflammation. An untargeted metabolite study of house dust mite-pulsed dendritic cells identified itaconate as one of the most abundant polar metabolites that may reduce mitochondrial oxidative damage in one of their experiments. It was also discovered that itaconate’s immunomodulatory activity was translated in vivo, with intranasal treatment of 4-octyl itaconate 4-OI following antigen priming attenuating the symptoms of house dust mite-induced airway illness and Th2 immune response.
Hence we can see that research is important in gaining a better understanding of allergic asthma and is critical for enhancing our understanding of the disease, discovering novel therapies, and researchers like Dr. Mishra are making dedicated efforts to help improve outcomes for those living with allergic asthma.
